These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39174596)

  • 21. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
    Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
    Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model.
    Zhao J; Wen X; Li T; Shi S; Xiong C; Wang YA; Li C
    ACS Omega; 2020 Apr; 5(15):8474-8482. PubMed ID: 32337408
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical PET imaging with the novel human antibody
    Kelly MP; Makonnen S; Hickey C; Arnold TC; Giurleo JT; Tavaré R; Danton M; Granados C; Chatterjee I; Dudgeon D; Retter MW; Ma D; Olson WC; Thurston G; Kirshner JR
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and first-in-human evaluation of
    Zhou M; Wang X; Chen B; Xiang S; Rao W; Zhang Z; Liu H; Fang J; Yin X; Deng P; Zhang X; Hu S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4312-4324. PubMed ID: 35831714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immuno-PET Imaging of
    Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
    Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-PET imaging of
    Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
    J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
    Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
    Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [
    Wang Y; Zhang Y; Chen Y; Wang S; Liu W; Liu Z; Hu M
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3161-3175. PubMed ID: 38713298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1.
    Luo H; Yang C; Kuang D; Shi S; Chan AW
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2735-2745. PubMed ID: 35089375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
    Wei J; Wang YH; Lee CY; Truillet C; Oh DY; Xu Y; Ruggero D; Flavell RR; VanBrocklin HF; Seo Y; Craik CS; Fong L; Wang CI; Evans MJ
    Mol Imaging Biol; 2020 Dec; 22(6):1553-1561. PubMed ID: 32813112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.
    Bridoux J; Broos K; Lecocq Q; Debie P; Martin C; Ballet S; Raes G; Neyt S; Vanhove C; Breckpot K; Devoogdt N; Caveliers V; Keyaerts M; Xavier C
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive PD-L1 quantification using [
    Mishra A; Gupta K; Kumar D; Lofland G; Sharma AK; Solnes LB; Rowe SP; Forde PM; Pomper MG; Gabrielson EW; Nimmagadda S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 39. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.